Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + capecitabine + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A triple-combination regimen consisting of bevacizumab (an anti-angiogenic agent), capecitabine (a chemotherapeutic agent), and trastuzumab (a HER2-targeted monoclonal antibody). This combination has been studied primarily for HER2-positive breast cancer and gastroesophageal cancers, showing promising efficacy and an acceptable safety profile.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on bevacizumab + capecitabine + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + capecitabine + trastuzumab.